<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00961298</url>
  </required_header>
  <id_info>
    <org_study_id>RC-4656</org_study_id>
    <nct_id>NCT00961298</nct_id>
  </id_info>
  <brief_title>An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder</brief_title>
  <official_title>An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West Penn Allegheny Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West Penn Allegheny Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to evaluate the effectiveness of duloxetine in treating subjects
      with both Irritable Bowel Syndrome (IBS) and Generalized Anxiety Disorder (GAD). The
      investigators hypothesize that duloxetine as a single therapeutic agent will effectively
      target pain and other core symptoms of IBS as well as GAD in this patient population with
      both conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Generalized Anxiety Disorder (GAD) is commonly associated with Irritable Bowel Syndrome(IBS).
      The etiology of IBS remains unknown and it is often refractory to treatment. Duloxetine has
      demonstrated efficacy in the treatment of GAD as well as other pain disorders including
      fibromyalgia and diabetic neuropathy.

      We plan to study 30 subjects with diagnoses of IBS and GAD between the ages of 18 and 65
      years. There will be a single-blind placebo-run-in for the first 2 weeks, followed by
      open-label duloxetine for 12 weeks flexibly titrated to 120 mg/day. Subjects will be informed
      that they will receive placebo for 2 weeks during the trial. All study visits will be at
      Allegheny General Hospital Department of Psychiatry. The study consists of a total of nine
      office visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impression Scale</measure>
    <time_frame>endpoint [12 weeks]</time_frame>
    <description>The scale consists of two parts the first part being Severity of Illness and the second part is Global Improvement. We report the Global improvement scale.
The Global Improvement is a 1-7 change scale of global improvement since inclusion in the project ranging with 1 &quot;very much improved&quot;, 4 &quot;no change&quot;, and 7 &quot;very much worse.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Rating Scale</measure>
    <time_frame>endpoint [12 weeks]</time_frame>
    <description>The HAM-A is a 14 question scale with five responses. Responses range from 0 &quot;not present&quot; to 4 &quot;very severe.&quot; The total score ranges from 0 to 56. Higher values represent a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Irritable Bowel Syndrome-Quality of Life Scale</measure>
    <time_frame>endpoint [12 weeks]</time_frame>
    <description>The IBS-QOL consists of 34 items, each with a five-point response scale. Ratings range from 1 &quot;not at all&quot; to 5 &quot;extremely&quot; or &quot;a great deal&quot; Higher responses on the scale indicate worse outcome. A minimal total score would be 34, maximum 170.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Irritable Bowel Syndrome Severity Scoring System</measure>
    <time_frame>endpoint [12 weeks]</time_frame>
    <description>This is a 4 item Likert scale with each assessment being 100 mm scored from measuring from 0 to 400. Higher numbers indicate worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two weeks of placebo run in followed by 12 weeks of Duloxetine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>All subjects will receive single-blind placebo for the first two weeks, and then duloxetine for the next 12 weeks, followed by an up to 2 week taper off of the duloxetine. After 2 weeks of placebo daily, subjects will receive 30 mg per day of duloxetine for two weeks, then titrated up to 60 mg per day of duloxetine at week 2. A dosage decrease to 30 mg daily is permittable after week 2. This will be a flexible dose study with doses of duloxetine progressively increasing at weeks 4 (90 mg daily) and 6 (120 mg daily) in conjunction with CGI-I scores, to reach 120 mg daily or the maximum tolerated dose, if less than 120 mg daily at Week 12. There will be a post-taper follow up appointment at Week 14. Of Note: Amendment IRB Approved 6/14/11 Study Ending at Week 12 with removal of Week 14 visit as part of study.</description>
    <arm_group_label>Duloxetine</arm_group_label>
    <other_name>Cymbalta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 years of age

          -  Active IBS diagnosis by a gastroenterologist

          -  Generalized Anxiety Disorder diagnosed by DSM-IV TR criteria and the Mini
             International Neuropsychiatric Interview for the DSM-IV (Mini)

          -  No changes in any non study medication once starting the study

        Exclusion Criteria:

          -  Current diagnoses of Major Depressive Disorder, Panic Disorder, Social Phobia, Post
             Traumatic Stress Disorder, Obsessive Compulsive Disorders, Eating Disorders,
             Somatoform Disorders, Drug or alcohol abuse or dependence, or severe personality
             disorder

          -  Lifetime history of any Bipolar Disorder or Psychotic Disorder

          -  Concurrent GI disorders falling outside of Rome III Functional GI disorders

          -  Pregnant women or sexually active female subjects not using medically acceptable
             method of contraception

          -  Current suicidal ideation

          -  Unstable medical condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alicia J Kaplan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Penn Allegheny Health System</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2009</study_first_submitted>
  <study_first_submitted_qc>August 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2009</study_first_posted>
  <results_first_submitted>March 14, 2014</results_first_submitted>
  <results_first_submitted_qc>June 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 9, 2014</results_first_posted>
  <last_update_submitted>June 8, 2014</last_update_submitted>
  <last_update_submitted_qc>June 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West Penn Allegheny Health System</investigator_affiliation>
    <investigator_full_name>Alicia Kaplan</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>IBS</keyword>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>GAD</keyword>
  <keyword>Generalized Anxiety Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were referred by a gastroenterologist who had Irritable Bowel Syndrome and anxiety.</recruitment_details>
      <pre_assignment_details>Two participants were considered screen failures and were not entered into the placebo run in phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Arm</title>
          <description>Every study eligible subject entered a two week placebo run in followed by 12 weeks treatment intervention with Duloxetine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Two Week Placebo Run in</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>12 Weeks Duloxetine Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm</title>
          <description>every subject had a two week placebo run in followed by 12 weeks treatment intervention with Duloxetine.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.54" spread="12.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Global Impression Scale</title>
        <description>The scale consists of two parts the first part being Severity of Illness and the second part is Global Improvement. We report the Global improvement scale.
The Global Improvement is a 1-7 change scale of global improvement since inclusion in the project ranging with 1 &quot;very much improved&quot;, 4 &quot;no change&quot;, and 7 &quot;very much worse.&quot;</description>
        <time_frame>endpoint [12 weeks]</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>every study eligible subject had a two week placebo run in followed by 12 weeks treatment intervention with Duloxetine.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression Scale</title>
          <description>The scale consists of two parts the first part being Severity of Illness and the second part is Global Improvement. We report the Global improvement scale.
The Global Improvement is a 1-7 change scale of global improvement since inclusion in the project ranging with 1 &quot;very much improved&quot;, 4 &quot;no change&quot;, and 7 &quot;very much worse.&quot;</description>
          <population>per protocol</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.64" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Anxiety Rating Scale</title>
        <description>The HAM-A is a 14 question scale with five responses. Responses range from 0 &quot;not present&quot; to 4 &quot;very severe.&quot; The total score ranges from 0 to 56. Higher values represent a worse outcome.</description>
        <time_frame>endpoint [12 weeks]</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>every study eligible subject had a two week placebo run in followed by 12 weeks treatment intervention with Duloxetine.</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Anxiety Rating Scale</title>
          <description>The HAM-A is a 14 question scale with five responses. Responses range from 0 &quot;not present&quot; to 4 &quot;very severe.&quot; The total score ranges from 0 to 56. Higher values represent a worse outcome.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.75" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Irritable Bowel Syndrome-Quality of Life Scale</title>
        <description>The IBS-QOL consists of 34 items, each with a five-point response scale. Ratings range from 1 &quot;not at all&quot; to 5 &quot;extremely&quot; or &quot;a great deal&quot; Higher responses on the scale indicate worse outcome. A minimal total score would be 34, maximum 170.</description>
        <time_frame>endpoint [12 weeks]</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>every study eligible subject had a two week placebo run in followed by 12 weeks treatment intervention with Duloxetine.</description>
          </group>
        </group_list>
        <measure>
          <title>Irritable Bowel Syndrome-Quality of Life Scale</title>
          <description>The IBS-QOL consists of 34 items, each with a five-point response scale. Ratings range from 1 &quot;not at all&quot; to 5 &quot;extremely&quot; or &quot;a great deal&quot; Higher responses on the scale indicate worse outcome. A minimal total score would be 34, maximum 170.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.73" spread="19.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Irritable Bowel Syndrome Severity Scoring System</title>
        <description>This is a 4 item Likert scale with each assessment being 100 mm scored from measuring from 0 to 400. Higher numbers indicate worse outcome.</description>
        <time_frame>endpoint [12 weeks]</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>every study eligible subject had a two week placebo run in followed by 12 weeks treatment intervention with Duloxetine.</description>
          </group>
        </group_list>
        <measure>
          <title>Irritable Bowel Syndrome Severity Scoring System</title>
          <description>This is a 4 item Likert scale with each assessment being 100 mm scored from measuring from 0 to 400. Higher numbers indicate worse outcome.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187.09" spread="54.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>within 14 weeks.</time_frame>
      <desc>patient interview at study visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment Arm</title>
          <description>every study eligible subject had a two week placebo run in followed by 12 weeks treatment intervention with Duloxetine.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>other</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>weight gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A limitation of this pilot study was its small sample size and open label design. Another limitation may be that the patient sample is not representative of a true cross section of the GAD population as a whole.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Alicia Kaplan MD</name_or_title>
      <organization>Allegheny General Hospital</organization>
      <phone>412-330-4069</phone>
      <email>akaplan@wpahs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

